Metacrine Stock Price

0.19 (5.37%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 183,843
Bid Price 3.62
Ask Price 3.73
News -
Day High 3.80


52 Week Range


Day Low 3.53
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Metacrine Inc MTCR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.19 5.37% 3.73 18:09:58
Open Price Low Price High Price Close Price Prev Close
3.54 3.53 3.80 3.71 3.54
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,213 183,843 $ 3.65 $ 671,870 - 2.59 - 11.00
Last Trade Time Type Quantity Stock Price Currency
18:02:45 formt 800 $ 3.73 USD


Draw Mode:

Metacrine Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 98.94M 26.53M 13.70M $ - $ - 23.20 0.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 13.60%

more financials information »

Metacrine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MTCR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.613.803.40023.53192,4980.123.32%
1 Month3.,8900.6320.32%
3 Months2.854.122.593.28230,8470.8830.88%
6 Months4.174.84252.593.56211,695-0.44-10.55%
1 Year10.0511.002.594.62140,973-6.32-62.89%
3 Years14.3916.192.595.31145,081-10.66-74.08%
5 Years14.3916.192.595.31145,081-10.66-74.08%

Metacrine Description

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211021 02:33:52